Department of Obstetrics and Gynaecology, Armed Forces Medical College, Pune, Maharashtra, India.
Indian J Pharmacol. 2020 Nov-Dec;52(6):467-471. doi: 10.4103/ijp.IJP_263_20.
Mother-to-child transmission of HIV has witnessed a significant reduction due to effective antiretroviral therapy (ART). Efavirenz has been introduced as a part of ART since last few years in the national Prevention of Parent to Child Transmission (PPTCT) program for pregnant women living with HIV. However, data related to adverse pregnancy outcomes associated with efavirenz-based ART are limited in the Indian scenario. The present study evaluated pregnancy outcomes in HIV-infected pregnant women who were given efavirenz-based ART during pregnancy.
It is a retrospective, observational, analytic study carried out at a referral hospital in Western India. Collection of data was done for a period of 5 years, and various adverse outcomes were studied which included preterm delivery, low birth weight (LBW), stillbirths, congenital anomaly, and neonatal death.
This study showed a preterm birth rate of 19% and LBW in 36% of cases. There was no significant association with congenital anomaly, stillbirth, or neonatal death.
There was an association of exposure to efavirenz with an increased incidence of adverse pregnancy outcomes, especially LBW infants. This study emphasizes the requirement of large prospective studies to investigate fetomaternal outcomes in pregnant women exposed to efavirenz.
由于有效的抗逆转录病毒疗法(ART),艾滋病毒母婴传播已显著减少。在过去几年中,依非韦伦已被纳入国家预防母婴传播(PPTCT)计划,作为艾滋病毒感染孕妇的 ART 的一部分。然而,在印度的情况下,与依非韦伦为基础的 ART 相关的不良妊娠结局的数据有限。本研究评估了在怀孕期间接受依非韦伦为基础的 ART 的艾滋病毒感染孕妇的妊娠结局。
这是在印度西部一家转诊医院进行的回顾性、观察性、分析性研究。数据收集时间为 5 年,研究了各种不良结局,包括早产、低出生体重(LBW)、死产、先天畸形和新生儿死亡。
本研究显示早产率为 19%,LBW 发生率为 36%。与先天畸形、死产或新生儿死亡无显著关联。
接触依非韦伦与不良妊娠结局发生率增加有关,尤其是 LBW 婴儿。这项研究强调需要进行大型前瞻性研究,以调查接触依非韦伦的孕妇的母婴结局。